NASDAQ:ACRV | Free Cash Flow | Acrivon Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2021-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$20.54M$14,000.00-$20.55M
2025-12-31-$15.24M$219,000.00-$15.46M
2025-03-31-$19.54M$58,000.00-$19.59M
2024-12-31-$17.36M$827,000.00-$18.19M
2024-03-31-$17.08M$815,000.00-$17.9M
2023-12-31-$12.37M$1.15M-$13.52M
2023-03-31-$11.36M$25,000.00-$11.38M
2022-12-31-$9.35M$251,000.00-$9.61M
2022-03-31-$8.42M$415,000.00-$8.83M
2021-12-31-$3.63M$137,000.00-$3.76M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$63.67M$1.67M-$65.33M
2024-12-31-$65.67M$2.77M-$68.44M
2023-12-31-$42.64M$1.29M-$43.93M
2022-12-31-$30.12M$2.17M-$32.28M
2021-12-31-$13.98M$238,000.00-$14.22M